High Glucose Enhances Thrombin Responses via Protease-Activated Receptor-4 in Human Vascular Smooth Muscle Cells
Authors:
- Bernhard H. RauchBernhard H. Rauch
- Thomas GenschTGThomas Gensch
- Luru DaiLDLuru Dai
- Ellen BretschneiderEBEllen Bretschneider
- Christina Francisca VogelaarCVChristina Francisca Vogelaar
- Karsten SchrörKSKarsten Schrör
- Anke C. RosenkranzARAnke C. Rosenkranz
- 1 March 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 31 (3) , 624-633
Abstract
Objective—: Diabetes is associated with vascular remodeling and increased thrombin generation. Thrombin promotes vascular smooth muscle cell (SMC) mitogenesis and migration via protease-activated receptors (PAR)-1, PAR-3, and PAR-4. We investigated the effect of high glucose on expression and function of vascular thrombin receptors. Methods and Results—: In human vascular SMCs, high glucose (25 versus 5.5 mmol/L) induced a rapid and sustained increase in PAR-4 mRNA, protein, and cell surface expression. PAR-1 and PAR-3 expression were not changed. High glucose pretreatment (48 hours) enhanced thrombin or PAR-4–activating peptide but not PAR-1–activating peptide evoked intracellular calcium mobilization, migration, and tumor necrosis factor α gene expression. This enhancement of thrombin-stimulated migration and gene expression by high glucose was abolished by endogenous PAR-4 knockdown. PAR-4 regulation was prevented by inhibition of protein kinase (PK)C-β and -δ isoforms or nuclear factor (NF)κB. Nuclear translocation of NFκB in high glucose–stimulated SMCs led to PKC-dependent NFκB binding to the PAR-4 promoter in a chromatin immunoprecipitation assay. Furthermore, in situ hybridization and immunohistochemistry confirmed high abundance of PAR-4 in human diabetic vessels as compared with nondiabetic vessels. Conclusion—: High glucose enhances SMC responsiveness to thrombin through transcriptional upregulation of PAR-4, mediated via PKC-β, -δ, and NFκB. This may play an important role in the vascular complications of diabetes.Keywords
This publication has 29 references indexed in Scilit:
- Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE−/− miceAtherosclerosis, 2009
- Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFATCardiovascular Research, 2009
- Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary SyndromeDiabetes Care, 2008
- Inhibiting Protease-Activated Receptor 4 Limits Myocardial Ischemia/Reperfusion Injury in Rat Hearts by Unmasking Adenosine SignalingThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Cytokine upregulation of proteinase‐activated‐receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinaseβin human endothelial cellsBritish Journal of Pharmacology, 2007
- Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerizationProceedings of the National Academy of Sciences, 2007
- Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cellsThrombosis and Haemostasis, 2003
- Nuclear factor-κB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectorisAtherosclerosis, 2002
- PDGF‐induced Akt phosphorylation does not activate NF‐κB in human vascular smooth muscle cells and fibroblastsFEBS Letters, 2000
- Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetesLife Sciences, 2000